Table 2.

Results of antiviral treatment of HCV-related glomerulopathy

Author/Ref. No.PatientsDrug DosesViral ResponseRenal Response
Misiani et al. (132)20, follow-up: 24 to 48 wkIFN-α-2a 1.5 MU for one week and 3 MU for 23 wk thrice weeklySVR N/A Viremia relapse in all patients within 1 yrNonsignificant decrease in proteinuria compared with no IFN-treated patients. S. creat. decreased
Johnson et al. (133)20, follow-up: up to 18 monthIFN-α 3 MU for 6 to 12 moSVR 0% (EVR 30%)Proteinuria reduced in patients with EVR; nephrotic syndrome recurred in 3 of 6 patients with relapsed viremia. S. creat. unchanged
Komatsuda et al. (134)5, follow-up: N/AIFN-α 6 · 102 every day for 24 wkNo responseNo response
Mazzaro et al. (135)7, follow-up: N/ALymphoblastoid IFN 3 MU thrice weekly for 6 moEVR 2 pt with SVR in 1 of themProteinuria decreased in 5 pt; Relapse in all patients at the end of treatment. S. creat. unchanged
Sabry et al. (136)20, follow-up: N/AIFN-α for 3 mo, in case of no-response addition of RBV 15 mg/kg with total duration 12 moSVR N/A; EVR in 4 pt only on IFN and in 1 on IFN + RBVProteinuria markedly reduced; S. creat. unchanged; No data on follow-up
Bruchfeld et al. (44)7, follow-up: up to 24 monthsIFN-α-2b 3 MU (n = 4) or 1.5 MU (n = 1) thrice weekly or PEG-IFN-α-2b 50 μg once a week (n = 2) RBV 200 to 800 mg daily for 24 wk to 15 moSVR 71.4% (5 pt)Proteinuria markedly reduced; hematuria disappears in 6 of 7 patients; GFR improved in 3 pt and stable in others. Results stable at follow-up
Rossi et al. (137)3, follow-up: 26 monthsRBV 15 mg/kg per d for 4 mo with subsequent addition of IFN-α-2b 3 MU three times a week for 12 moSVR in all patientsProteinuria decreased; stable regression of proteinuria for more than 24 mo; GFR increased
Lopes et al. (138)2, follow-up: 24 monthsIFN-α-2b 3 MU 3 times a week, and RBV 1000 mg/d for 12 moSVR in all patientsProteinuria substantially decreased; on follow-up relapse of proteinuria in 1 patient at 24 mo
Alric et al. (139)18, follow-up: minimum 6 moIFN (3 MU 3 times/wk, n = 14) or PEG-IFN (1.5 μg/kg per wk, n = 4) RBV 600 to 1000 mg/d for 6 to 24 moSVR 66.7%Statistically significant reduction of proteinuria only in SVR responders. S. creat. unchanged
Cua et al. (140)1, follow-up: N/APEG-IFN-α-2b 1.5 μg/kg per wk 44 mo (after unsuccessful treatment by IFN)N/ADisappearance of proteinuria
Garini et al. (141)4, follow-up: 12 monthsIFN-α 3 MU thrice weekly (n = 2) plus RBV 15 mg/kg per d or PEG-IFN-α-2a 100 μg/wk + RBV 800 mg/day (n = 1) or PEG-IFN-α-2a 80 μg/wk plus RBV 15 mg/kg per d (n = 1) for 24 to 48 wkSVR in 3 of 4 patientsProteinuria decreased in 3 pt at the end of therapy; proteinuria relapsed in one patient with no HCV RNA eradication
  • EVR, end-of-treatment viral response; SVR, sustained viral response; GFR, glomerular filtration rate; N/A, not available; S. creat., serum creatinine; IFN, interferon; PEG-IFN, peginterferon; RBV, ribavirin.